Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Graphite Bio, Inc. (GRPH : NSDQ)

• Company Description    Graphite Bio Inc. is a clinical-stage, next-generation gene editing company focused on therapies to treat or cure serious diseases. Graphite Bio Inc. is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 69

• Price / Volume Information    Yesterday's Closing Price: $2.48 Daily Weekly Monthly 20 Day Moving Average: 826,160 shares Shares Outstanding: 57.97 (millions) Market Capitalization: $143.77 (millions) Beta: 52 Week High: $34.00 52 Week Low: $2.19 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -37.06% -31.03% 12 Week -72.38% -70.03% Year To Date -80.05% -76.27%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 201 Haskins Way Suite 210 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-484-0886 fax: - ir@graphitebio.com http://www.graphitebio.com

• General Corporate Information    Officers Josh Lehrer - Chief Executive Officer;President and Director Perry Karsen - Chairman of the Board and Director Philip P. Gutry - Chief Business Officer; Head of Finance & Investor Abraham Bassan - Director Jerel Davis - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 38870X104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 57.97 Most Recent Split Date: (:1) Beta: Market Capitalization: $143.77 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.45 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.66 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 25.90% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.40 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -37.14% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -20.17 12/31/21 - -24.33 09/30/21 - - ROA 03/31/22 - -19.42 12/31/21 - -23.48 09/30/21 - - Current Ratio 03/31/22 - 26.93 12/31/21 - 31.44 09/30/21 - 35.60 Quick Ratio 03/31/22 - 26.93 12/31/21 - 31.44 09/30/21 - 35.60 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 6.23 12/31/21 - 6.61 09/30/21 - 6.89 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©